Arbutus Biopharma (NASDAQ:ABUS) Releases Earnings Results, Beats Estimates By $0.01 EPS

Arbutus Biopharma (NASDAQ:ABUS) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01, Zacks reports. The business had revenue of $1.57 million for the quarter, compared to analyst estimates of $2.20 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%.

Arbutus Biopharma Trading Up 5.0 %

NASDAQ:ABUS traded up $0.17 during trading hours on Friday, hitting $3.44. The stock had a trading volume of 474,998 shares, compared to its average volume of 1,032,135. The company has a market cap of $650.91 million, a PE ratio of -7.99 and a beta of 1.93. The business has a 50 day simple moving average of $3.33 and a two-hundred day simple moving average of $3.58. Arbutus Biopharma has a 1-year low of $2.30 and a 1-year high of $4.73.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Chardan Capital restated a “buy” rating and set a $5.00 price objective on shares of Arbutus Biopharma in a report on Friday. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. Finally, StockNews.com lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 13th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Arbutus Biopharma has an average rating of “Moderate Buy” and an average price target of $5.50.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.